Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
13
05
2021
accepted:
13
08
2021
pubmed:
22
9
2021
medline:
17
11
2021
entrez:
21
9
2021
Statut:
ppublish
Résumé
Inherited epidermolysis bullosa (EB) comprises rare disorders that manifest with fragility and blistering of the skin and mucous membranes, with variable clinical severity. Management of EB is challenging due to disease rarity and complexity, the wide range of extracutaneous manifestations and a profound impact on daily life for the patient and family members. Although reference centres providing multidisciplinary care for EB exist in each European country, it is common for healthcare professionals that are not specialized in this rare disorder to treat EB patients. Here, experts of the European Reference Network for Rare and Undiagnosed Skin Diseases (ERN-Skin, https://ern-skin.eu) propose practical recommendations for the diagnosis and management of the commonest clinical issues, skin blisters and wounds, oral manifestations, pain and itch.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2349-2360Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Has C, Bauer JW, Bodemer C et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 2020; 183: 614-627.
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol 2009; 61: 367-384; quiz 385-6.
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol 2009; 61: 387-402; quiz 403-4.
Mellerio JE, El Hachem M, Bellon N et al. Emergency management in epidermolysis bullosa: consensus clinical recommendations from the European reference network for rare skin diseases. Orphanet J Rare Dis 2020; 15: 142.
Has C, Liu L, Bolling MC et al. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. Br J Dermatol 2020; 182: 574-592.
Rossi S, Castiglia D, Pisaneschi E et al. Immunofluorescence mapping, electron microscopy and genetics in the diagnosis and sub-classification of inherited epidermolysis bullosa: a single-centre retrospective comparative study of 87 cases with long-term follow-up. J Eur Acad Dermatol Venereol 2021; 35: 1007-1016.
El Hachem M, Zambruno G, Bourdon-Lanoy E et al. Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet J Rare Dis 2014; 9: 76.
Pope E, Lara-Corrales I, Mellerio J et al. A consensus approach to wound care in epidermolysis bullosa. J Am Acad Dermatol 2012; 67: 904-917.
Denyer J. Best practice guidelines for skin and wound care in epidermolysis bullosa. An International Consensus. Wounds International; 2017. https://www.woundsinternational.com/resources/details/best-practice-guidelines-skin-and-wound-care-in-epidermolysis-bullosa
Pope E, Lara-Corrales I, Mellerio JE, Martinez AE, Sibbald C, Sibbald RG. Epidermolysis bullosa and chronic wounds. Adv Skin Wound Care 2013; 26: 177-188; quiz 189-90.
Reimer A, Hess M, Schwieger-Briel A et al. Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study. Br J Dermatol 2020; 182: 1437-1448.
Woo KY, Sibbald RG. A cross-sectional validation study of using NERDS and STONEES to assess bacterial burden. Ostomy Wound Manag 2009; 55: 40-48.
Sibbald RG, Woo K, Ayello EA. Increased bacterial burden and infection: the story of NERDS and STONES. Adv Skin Wound Care 2006; 19: 447-461; quiz 461-3.
Mellerio JE, Robertson SJ, Bernardis C et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br J Dermatol 2016; 174: 56-67.
Solis DC, Gorell ES, Teng C et al. Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol 2021; 38: 704-706.
Bruckner AL, Losow M, Wisk J et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis 2020; 15: 1.
Papanikolaou M, Onoufriadis A, Mellerio JE et al. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol 2021; 184: 816-825.
Martin K, Geuens S, Asche JK et al. Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines. Orphanet J Rare Dis 2019; 14: 133.
Khan MT, O'Sullivan M, Faitli B et al. Creating new guidelines on how best to treat foot symptoms in people with EB. Br J Dermatol 2020; 182: e89-e114.
Khan MT, O’Sullivan M, Faitli B et al. Foot care in epidermolysis bullosa: evidence-based guideline. Br J Dermatol 2020; 182: 593-604.
Fumarola S, Allaway R, Callaghan R et al. Overlooked and underestimated: medical adhesive-related skin injuries. J Wound Care 2020; 29: S1-S24.
Klode J, Schöttler L, Stoffels I, Körber A, Schadendorf D, Dissemond J. Investigation of adhesion of modern wound dressings: a comparative analysis of 56 different wound dressings. J Eur Acad Dermatol Venereol 2011; 25: 933-939.
Reimer A, Laszig R, Pfeiffer J et al. Successful multidisciplinary treatment of chronic facial wounds in junctional epidermolysis bullosa. Acta Derm Venereol 2018; 98: 711-712.
Krämer S, Lucas J, Gamboa F et al. Clinical practice guidelines: Oral health care for children and adults living with epidermolysis bullosa. Spec Care Dentist 2020; 40(Suppl 1): 3-81.
Schräder NHB, Yuen WY, Jonkman MF. Pain quality assessment scale for epidermolysis bullosa. Acta Derm Venereol 2018; 98: 346-349.
Mahajan C, Dash HH. Procedural sedation and analgesia in pediatric patients. J Pediatr Neurosci 2014; 9: 1-6.
von Bischhoffshausen S, Ivulic D, Alvarez P et al. Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy. Brain 2017; 140: 1238-1251.
Noel M, Chambers CT, Petter M, McGrath PJ, Klein RM, Stewart SH. Pain is not over when the needle ends: a review and preliminary model of acute pain memory development in childhood. Pain Manag 2012; 2: 487-497.
Noel M, Chambers CT, McGrath PJ, Klein RM, Stewart SH. The influence of children's pain memories on subsequent pain experience. Pain 2012; 153: 1563-1572.
Bieri D, Reeve RA, Champion DG, Addicoat L, Ziegler JB. The Faces Pain Scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties. Pain 1990; 41: 139-150.
Manworren RCB, Hynan LS. Clinical validation of FLACC: preverbal patient pain scale. Pediatr Nurs 2003; 29: 140-146.
Attal N, Bouhassira D, Baron R. Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol 2018; 17: 456-466.
Cohn HI, Teng JMC. Advancement in management of epidermolysis bullosa. Curr Opin Pediatr 2016; 28: 507-516.
Goldschneider KR, Good J, Harrop E et al. Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med 2014; 12: 178.
Khan F, Mehan A. Addressing opioid tolerance and opioid-induced hypersensitivity: recent developments and future therapeutic strategies. Pharmacol Res Perspect 2021; 9: e00789.
Chiu YK, Prendiville JS, Bennett SM, Montgomery CJ, Oberlander TF. Pain management of junctional epidermolysis bullosa in an 11-year-Old boy. Pediatr Dermatol 1999; 16: 465-468.
Schräder NHB, Duipmans JC, Molenbuur B, Wolff AP, Jonkman MF. Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases. Br J Dermatol 2019; 180: 922-924.
Martinez AE. Time to drop the stigma: cannabinoids are drugs that may alleviate pain in people with epidermolysis bullosa. Br J Dermatol 2019; 180: 711-712.
Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol 2018; 35: e224-e227.
Fine JD, Johnson LB, Weiner M, Suchindran C. Gastrointestinal complications of inherited epidermolysis bullosa: cumulative experience of the National Epidermolysis Bullosa Registry. J Pediatr Gastroenterol Nutr 2008; 46: 147-158.
Conway A, Rolley J, Sutherland JR. Midazolam for sedation before procedures. Cochrane Database Syst Rev 2016: CD009491.
Wetzel RC. Anesthesia, perioperative care and sedation. In: Nelson Textbook of Pediatrics, 20th edn. Saunders, Philadelphia, PA; 2016: 416-422.
Oliveira J. e Silva L, Lee JY, Bellolio F, Homme JL, Anderson JL. Intranasal ketamine for acute pain management in children: a systematic review and meta-analysis. Am J Emerg Med 2020; 38: 1860-1866.
Moreno Artero E, Schinkel N, Chaumon S et al. Efficacy of topical ropivacaine in children and young adults with hereditary epidermolysis bullosa. Br J Dermatol 2021;184: 550-552.
Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009; 361: 1415-1416.
Chiou AS, Choi S, Barriga M et al. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: a randomized clinical trial. J Am Acad Dermatol. 2020; 82: 1415-1421.
Foam Dressings. WoundSource. URL https://www.woundsource.com/product-category/dressings/foam-dressings (last accessed: 8 May 2021).
Vowden K, Vowden P. Wound dressings: principles and practice. Surgery - Oxford International Edition 2017; 35: 489-494.
Alginates. WoundSource. URL https://www.woundsource.com/product-category/dressings/alginates (last accessed: 8 May 2021).
Weng T-C, Chen C-C, Toh H-S, Tang H-J. Ibuprofen worsens Streptococcus pyogenes soft tissue infections in mice. J Microbiol Immunol Infect 2011; 44: 418-423.